GPP
ELVN icon

Great Point Partners’s Enliven Therapeutics ELVN Stock Holding History

Great Point Partners’s Portfolio ELVN Stock Details ELVN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$3.55M Buy
+70,000
New +$2.97M 0.67% 37

Other funds holding ELVN

Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
O
OrbiMed New York $5.4B AUM 163.13% 1-Year Est. Return
PCH
Polar Capital Holdings London, United Kingdom $42.4B AUM 181.11% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
VPC
Vestal Point Capital New York $4.28B AUM 239% 1-Year Est. Return
CC
Commodore Capital New York $1.68B AUM 375.52% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Citadel Advisors
Citadel Advisors Miami, Florida $875B AUM 40.91% 1-Year Est. Return
FFM
Fairmount Funds Management West Conshohocken, Pennsylvania $1.51B AUM 546.08% 1-Year Est. Return

Great Point Partners's ELVN Position: Q2 2026 in Review

Great Point Partners opened a new position in Enliven Therapeutics (ELVN) in Q2 2026: 70,000 shares worth $3.55M. The stake represents 0.67% of the portfolio and ranks #37 among its holdings.

210 funds tracked by Wall St. Rank hold ELVN as of Q2 2026.

  • Great Point Partners held 70,000 shares of Enliven Therapeutics worth $3.55M as of Q2 2026.
  • Enliven Therapeutics was a new Great Point Partners position in Q2 2026.
  • Enliven Therapeutics made up 0.67% of Great Point Partners's portfolio in Q2 2026, its #37 holding.
  • 210 funds tracked by Wall St. Rank held Enliven Therapeutics as of Q2 2026.

Based on Great Point Partners's 13F filing for Q2 2026, filed 14 Aug 2026.